Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Dow raised at JPMorgan, Rocket upgraded to Hold: 4 big analyst picks

Published 09/25/2023, 05:55 AM
© Reuters.
DOW
-
CDE
-
AZN
-
RKT
-

By Davit Kirakosyan

Here is your Pro Recap of the biggest analyst picks you may have missed since Friday: upgrades at Dow, Rocket, AstraZeneca, and Coeur Mining.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Dow raised to Overweight at JPMorgan

Dow (NYSE:DOW) shares rose more than 1% pre-market today after JPMorgan upgraded the company to Overweight from Neutral with a price target of $55.00.

The firm noted that Dow has faced challenges such as weaker demand in China and Europe, domestic capacity increases, replenished inventories, and a sluggish global economy. However, the bank believes “the recent downward movement in equity values has given investors an opportunity to purchase Dow shares at a reasonable valuation”.

According to JPMorgan, the company has a robust balance sheet, offers a 5.6% dividend yield, and the potential for positive responses to higher oil prices.

Rocket upgraded to Hold

CFRA upgraded Rocket (NYSE:RKT) to Hold from Sell with a price target of $8.00, as reported in real-time on InvestingPro. Shares jumped more than 8% pre-market today.

The firm sees Rocket's fair value closer to its target after a 30% drop from August highs. CFRA maintains its earnings estimates, projecting a loss of $0.15 per share in 2023 and a profit of $0.45 per share in 2024, supported by revenue estimates of $3.97 billion and $5.2B.

Despite challenges in the mortgage market, the firm believes Rocket's diversified businesses and available liquidity resources position it well.

InvestingPro | Always Know First

Two more upgrades

AstraZeneca (NASDAQ:AZN) shares rose more than 1% pre-market today after Jefferies upgraded the company to Buy from Neutral and raised its price target to $80.00 from $66.50.

Last week, the company reported positive high-level results from the TROPION-Breast01 Phase III trial.

RBC Capital upgraded Coeur Mining (NYSE:CDE) to Outperform from Sector Perform with a price target of $4.00. As a result, shares surged more than 7% on Friday.

The expansion at Rochester is almost complete, and execution on the ramp up through mid-2024 is the key catalyst for the stock in our view. The site visit we attended highlighted the +$700m investment in throughput expansion, which should lead to +120% higher production once at full capacity in 2025.

In fast-moving markets, every second counts - and InvestingPro subscribers are always one step ahead with lightning-quick updates.

Start your free 7-day trial now.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.